These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39126937)

  • 1. Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis.
    Smoot K; Gervasi-Follmar T; Marginean H; Chen C; Cohan S
    Mult Scler Relat Disord; 2024 Oct; 90():105799. PubMed ID: 39126937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients.
    Adamczyk-Sowa M; Pierzchala K; Sowa P; Polaniak R; Kukla M; Hartel M
    J Physiol Pharmacol; 2014 Aug; 65(4):543-50. PubMed ID: 25179086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.
    Sánchez-López AL; Ortiz GG; Pacheco-Moises FP; Mireles-Ramírez MA; Bitzer-Quintero OK; Delgado-Lara DLC; Ramírez-Jirano LJ; Velázquez-Brizuela IE
    Arch Med Res; 2018 Aug; 49(6):391-398. PubMed ID: 30595364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
    Bahamonde C; Conde C; Agüera E; Lillo R; Luque E; Gascón F; Feijóo M; Cruz AH; Sánchez-López F; Túnez I
    Eur J Pharmacol; 2014 May; 730():26-30. PubMed ID: 24582759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis.
    Golan D; Staun-Ram E; Glass-Marmor L; Lavi I; Rozenberg O; Dishon S; Barak M; Ish-Shalom S; Miller A
    Brain Behav Immun; 2013 Aug; 32():180-5. PubMed ID: 23665342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial.
    Chang YS; Lin MH; Lee JH; Lee PL; Dai YS; Chu KH; Sun C; Lin YT; Wang LC; Yu HH; Yang YH; Chen CA; Wan KS; Chiang BL
    JAMA Pediatr; 2016 Jan; 170(1):35-42. PubMed ID: 26569624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Ostadmohammadi V; Soleimani A; Bahmani F; Aghadavod E; Ramezani R; Reiter RJ; Mansournia MA; Banikazemi Z; Soleimani M; Zaroudi M; Asemi Z
    J Ren Nutr; 2020 May; 30(3):242-250. PubMed ID: 31597622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of modified anti-inflammatory diet on fatigue, quality of life, and inflammatory biomarkers in relapsing-remitting multiple sclerosis patients: a randomized clinical trial.
    Mousavi-Shirazi-Fard Z; Mazloom Z; Izadi S; Fararouei M
    Int J Neurosci; 2021 Jul; 131(7):657-665. PubMed ID: 32249637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
    Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
    BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial.
    Wahls T; Scott MO; Alshare Z; Rubenstein L; Darling W; Carr L; Smith K; Chenard CA; LaRocca N; Snetselaar L
    Trials; 2018 Jun; 19(1):309. PubMed ID: 29866196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary interventions for multiple sclerosis-related outcomes.
    Parks NE; Jackson-Tarlton CS; Vacchi L; Merdad R; Johnston BC
    Cochrane Database Syst Rev; 2020 May; 5(5):CD004192. PubMed ID: 32428983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).
    Delgado D; Canham L; Cotterill N; Cottrell D; Drake MJ; Inglis K; Owen D; White P
    BMC Neurol; 2017 Mar; 17(1):63. PubMed ID: 28347292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis.
    Melamud L; Golan D; Luboshitzky R; Lavi I; Miller A
    J Neurol Sci; 2012 Mar; 314(1-2):37-40. PubMed ID: 22137446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis.
    Roostaei T; Sahraian MA; Hajeaghaee S; Gholipour T; Togha M; Siroos B; Mansouri S; Mohammadshirazi Z; Aghazadeh Alasti M; Harirchian MH
    Iran J Allergy Asthma Immunol; 2015 Dec; 14(6):589-95. PubMed ID: 26725556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.
    Adamczyk-Sowa M; Sowa P; Adamczyk J; Niedziela N; Misiolek H; Owczarek M; Zwirska-Korczala K
    J Physiol Pharmacol; 2016 Apr; 67(2):235-42. PubMed ID: 27226183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.